Shoals Technologies, Affirm Holdings, Apple And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Shoals…
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday’s session after the company reported worse-than-expected quarterly…
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Thursday. Shares of The…
Bath & Body Works, Designer Brands And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday. Shares…
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday. Shares…
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Allarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday’s pre-market session. The market value…
Reported Earlier, Pharming Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib
Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the completion of patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug
What’s Going On With Netherlands-Based Biopharma Company Pharming Shares Today?
Pharming Group (NASDAQ: PHAR) updated its full-year 2023 guidance, including RUCONEST and Joenja revenues, and a progress update on the
Pharming Group Updates Its FY23 Guidance, Expects Revenue To Increase By 19% YoY To Around $245M, With RUCONEST Revenues +10%, And Joenja Revenues Of ~$18M
Preliminary, unaudited cash and cash equivalents, together with restricted cash and marketable securities, are expected to total US$215.0 million at the end of 2023, compared to US$199.2 million a
Sijmen de Vries,
Pharming Group Expands Research On Leniolisib For Additional Primary Immunodeficiencies, Targets Phase 2 Trial Initiation In 2Q24
Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today the expansion of its rare disease pipeline with plans to develop